December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Initial results from the phase Ib/II study suggest ciltacabtagene autoleucel, an anti-BCMA CAR T-cell therapy, showed promising efficacy and a manageable safety profile in heavily pretreated patients with R/R MM.